Abstract
Objective: To evaluate the role of intravenous immunoglobulins in Rh hemolytic disease of newborn.Methods: The study included all DCT positive Rh isoimmunized babies admitted in the unit from August 2000 to February 2001. Intravenous immunoglobulins in the dose of 500 mg/kg on day 1 and day 2 of life in addition to the standard therapy. Babies who received IVIG were compared with those who did not receive IVIG for the peak bilirubin levels, duration of phototherapy, number of exchange transfusions, discharge PCV and the need for blood transfusions for late anemia till 1 months of age.Results: A total of 34 babies were eligible for the study. 8 babies received IVIG and 26 babies only standard treatment. The mean maximum bilirubin levels were significantly lower in the IVIG group compared to the group who received NO IVIG (16.52 ± 2.96 Vs 22.72 ± 8.84, p=0.004). Five babies in the IVIG group (62.5%) and 23 babies in the NO IVIG group required exchange transfusions (88.5%, p=0.014). 12 of the 26 babies in the NO IVIG group required multiple exchange transfusions while none of the babies in IVIG group required more one exchange transfusion (p=0.03). The mean duration of phototherapy was 165 ± 109 hours in the IVIG group as against 119 ± 56 hours in the NO IVIG group (p=0.29). Blood transfusion for anemia was more common in the IVIG group (37.5 % Vs 11.5% p=0.126) though the packed cell volumes at discharge were similar in both the groups (39.5 ±11 Vs 40 ± 5.1, P=0.92).Conclusion; Intravenous immunoglobulins is effective in decreasing the maximum bilirubin levels and the need for repeated exchange transfusions in Rh hemolytic disease of newborn. There is however an increased need for blood transfusions for late anemia in the babies treated with IVIG.
Similar content being viewed by others
References
Verma M, Chhatwal J, Singh D. Neonatal hyperbilirubinemia.Indian J Pediatr 1988;55:899–904.
Dagoglu T, Ovali F, Samanci N, and Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus hemolytic diseases.J Int Med Res 1995; 23(4): 264–271.
Rubo J, Albrecht K, Lasch P, Laufkottor E, Leititis J, Marson D. High dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease.J Pediatr 1992; 121(1): 93–97.
Urbaniak SJ. ADCG (K-cell) Lysis of human erythrocytes sensitized with rhesus alloantibodies. II.Investigation into the mechanism of lysis.Br J Hematology 1979; 42:315–328.
Tanyer G, Siklar Z, Dallar Y, Yildilmark Y, and Tiras U. Multi dose IVIG treatment in neonatal immune hemolytic jaundice.J Trap Pediatr 2001; 47:50–53.
Pishva N, Madani A, Homayoon. Prophylactic intravenous immunoglobulin in neonatal immune hemolytic jaundice.Im J Med Sci 2000; 25 (3&4): 129–133.
Ergaz Z, Arad I. Intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice.J Perinat Med 1993; 21(3): 183–187.
Voto LS, Sexer H, Ferreio G, Tavosnanska J, Orti J, Mathet ERet al. Neonatal administration of high-does intravenous immunoglobulin in rhesus hemolytic disease.J Perinat Med 1995; 23(6): 443–451.
Yap PL. Intravenous immunoglobulin and hepatitis C virus: An overview of transmission episodes with emphasis on manufacturing data.Clin Ther 1996; 18 (Suppl B): 43–58.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mukhopadhyay, K., Murki, S., Narang, A. et al. Intravenous immunoglobulins in rhesus hemolytic disease. Indian J Pediatr 70, 697–699 (2003). https://doi.org/10.1007/BF02724308
Issue Date:
DOI: https://doi.org/10.1007/BF02724308